Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Virtual Biopsy Market Growth From $0.79 Billion In 2026 To $1.23 Billion By 2030 At A CAGR Of 11.7%
The virtual biopsy market has experienced substantial expansion in recent years. It is projected to expand from $0.71 billion in 2025 to $0.79 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 11.9%. Historically, this growth can be ascribed to factors such as dependence on conventional biopsy methods, restricted capabilities of imaging technology, the escalating incidence of chronic illnesses, the development of hospital and diagnostic infrastructure, and the heightened need for precise cancer diagnoses.
The virtual biopsy market is projected for significant expansion in the coming years. Its valuation is set to reach $1.23 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.7%. This anticipated growth during the forecast period is fueled by several factors, including developments in imaging algorithms and AI analytics, the broadening of diagnostic applications in oncology and neurology, increasing use for cardiovascular and ophthalmological conditions, integration with personalized medicine strategies, and rising capital expenditure in research institutions and diagnostic facilities. Key trends anticipated within this period involve a greater embrace of non-invasive diagnostic methods, an escalating need for early disease identification, the combination of sophisticated imaging with predictive analytics, an extension of virtual biopsy utility across various therapeutic fields, and an intensified emphasis on patient comfort alongside quicker recovery.
Get A Free Sample Report With In-Depth Market Insights:
Virtual Biopsy Market Expansion Drivers: What’s Shaping Future Growth?
The increasing incidence of cancer-related conditions is anticipated to drive the expansion of the virtual biopsy market in the future. Oncological disorders refer to diseases involving uncontrolled growth and dissemination of abnormal cells within the body. This growth in oncological disorders is largely attributable to evolving lifestyles, including unhealthy eating habits, lack of physical exercise, smoking, and heightened exposure to environmental contaminants. Virtual biopsy supports the detection and oversight of these conditions through non-invasive, immediate imaging data, lessening the necessity for conventional tissue biopsies and simultaneously boosting diagnostic precision and patient well-being. For example, in January 2023, the U.S.-based digital health research firm Rock Health stated that 1,958,310 new cancer cases are forecast in the U.S. for 2023, representing an increase from approximately 1.9 million new cases in 2022. Consequently, the growing occurrence of oncological disorders is a key factor propelling the expansion of the virtual biopsy market.
Virtual Biopsy Market Segmentation: How Does The Market Break Down By Category?
The virtual biopsy market covered in this report is segmented –
1) By Target Thrapeutic Areas: Oncological Disorders, Neurological Disorders, Cardiovascular Disorders, Ophthalmological Disorders, Endocrine Disorders, Gastrointestinal Disorders, Other Target Therapeutic Areas
2) By Cancer Targeted: Solid Malignancies, Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Cancer, Other Cancer Targeteds
3) By Imaging Technologies: Magnetic Resonance Imaging, Computed Tomography, X-Ray, Ultrasound, Other Imaging Technologies
4) By End Users: Hospitals And Clinics, Research Institutes And Diagnostic Centers, Other End Users
Subsegments:
1) By Oncological Disorders: Lung Cancer, Breast Cancer, Prostate Cancer, Colorectal Cancer, Liver Cancer, Brain Tumors, Other Cancers
2) By Neurological Disorders: Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Epilepsy, Brain Injuries, Stroke, Other Neurological Conditions
3) By Cardiovascular Disorders: Coronary Artery Disease, Heart Failure, Arrhythmias, Aortic Aneurysm, Valvular Heart Disease, Myocardial Infarction, Other Cardiovascular Conditions
4) By Ophthalmological Disorders: Age-Related Macular Degeneration, Diabetic Retinopathy, Glaucoma, Retinal Vein Occlusion, Cataracts, Other Eye Disorders
5) By Endocrine Disorders: Diabetes Mellitus, Thyroid Disorders, Adrenal Gland Disorders, Pituitary Gland Disorders, Parathyroid Disorders, Other Endocrine Conditions
6) By Gastrointestinal Disorders: Inflammatory Bowel Disease, Colorectal Polyps, Gastric Ulcers, Liver Cirrhosis, Pancreatic Disorders, Hepatitis, Other Gastrointestinal Conditions
7) By Other Target Therapeutic Areas: Musculoskeletal Disorders, Renal Disorders, Pulmonary Disorders, Hematologic Disorders, Dermatological Disorders, Infectious Diseases, Other Miscellaneous Conditions
Virtual Biopsy Market Strategic Trends: What Defines The Next Growth Phase?
Leading companies within the virtual biopsy market are prioritizing the development of advanced technological solutions and obtaining crucial approvals, including for the magnetic resonance spectroscopy (MRS) platform, to boost non-invasive diagnostic precision and offer real-time analysis for prompt disease detection and personalized therapeutic strategies. Magnetic resonance spectroscopy (MRS) serves as a non-invasive imaging method that supports virtual biopsy by providing intricate molecular details of tissues, thereby facilitating accurate, real-time disease identification and ongoing surveillance without the necessity of invasive procedures. As an illustration, in November 2023, BrainSpec Inc., a US-based healthtech company, secured approval from the U.S. Food and Drug Administration (FDA) for its artificial intelligence (AI)-driven BrainSpec platform. This innovation leverages sophisticated artificial intelligence (AI) analysis of MR spectroscopy data to measure brain metabolites like 2-hydroxyglutarate, allowing for non-invasive virtual biopsies to diagnose conditions such as gliomas, alzheimer’s, and multiple sclerosis. The system is designed for seamless integration with standard magnetic resonance imaging (MRI) scanners, automates data processing, and delivers results within minutes. It also utilizes a comprehensive reference database of brain chemistry to further refine diagnostic accuracy.
Virtual Biopsy Market Key Participants And Competitive Landscape
Major companies operating in the virtual biopsy market are Siemens Healthineers AG, GE Healthcare, Canon Medical Systems, Philips Healthcare, Fujifilm Healthcare, Esaote SpA, Samsung Medison, Perspectum Ltd, QUIBIM SL, ImageBiopsy Lab GmbH, Deep Bio Inc, BrainSpec Inc, Oncoustics Inc, AI Metrics LLC, Zebra Medical Vision, Arterys Inc, Aidoc Medical, Viz ai, Subtle Medical, Gleamer AI
View The Full Virtual Biopsy Market Report:
Virtual Biopsy Market Geographic Analysis: Where Is Demand Accelerating Fastest?
North America was the largest region in the virtual biopsy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the virtual biopsy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
